247 related articles for article (PubMed ID: 29018057)
1. PD-1 Blockade Prevents the Development and Progression of Carcinogen-Induced Oral Premalignant Lesions.
Wang J; Xie T; Wang B; William WN; Heymach JV; El-Naggar AK; Myers JN; Caulin C
Cancer Prev Res (Phila); 2017 Dec; 10(12):684-693. PubMed ID: 29018057
[TBL] [Abstract][Full Text] [Related]
2. Targeting of CD40 and PD-L1 Pathways Inhibits Progression of Oral Premalignant Lesions in a Carcinogen-induced Model of Oral Squamous Cell Carcinoma.
Monteiro de Oliveira Novaes JA; Hirz T; Guijarro I; Nilsson M; Pisegna MA; Poteete A; Barsoumian HB; Fradette JJ; Chen LN; Gibbons DL; Tian X; Wang J; Myers JN; McArthur MJ; Bell D; William WN; Heymach JV
Cancer Prev Res (Phila); 2021 Mar; 14(3):313-324. PubMed ID: 33277316
[TBL] [Abstract][Full Text] [Related]
3. Local Anti-PD-1 Delivery Prevents Progression of Premalignant Lesions in a 4NQO-Oral Carcinogenesis Mouse Model.
Shi Y; Xie TX; Leach DG; Wang B; Young S; Osman AA; Sikora AG; Ren X; Hartgerink JD; Myers JN; Rangel R
Cancer Prev Res (Phila); 2021 Aug; 14(8):767-778. PubMed ID: 34021022
[TBL] [Abstract][Full Text] [Related]
4. Use of carcinogen-induced premalignant oral lesions in a dendritic cell-based vaccine to stimulate immune reactivity against both premalignant oral lesions and oral cancer.
Young MR
J Immunother; 2008; 31(2):148-56. PubMed ID: 18481384
[TBL] [Abstract][Full Text] [Related]
5. PD-1 blockade prevents the progression of oral carcinogenesis.
Dong Y; Wang Z; Mao F; Cai L; Dan H; Jiang L; Zeng X; Li T; Zhou Y; Chen Q
Carcinogenesis; 2021 Jun; 42(6):891-902. PubMed ID: 33993220
[TBL] [Abstract][Full Text] [Related]
6. Bitter Melon Prevents the Development of 4-NQO-Induced Oral Squamous Cell Carcinoma in an Immunocompetent Mouse Model by Modulating Immune Signaling.
Sur S; Steele R; Aurora R; Varvares M; Schwetye KE; Ray RB
Cancer Prev Res (Phila); 2018 Apr; 11(4):191-202. PubMed ID: 29061560
[TBL] [Abstract][Full Text] [Related]
7. Transient immunological and clinical effectiveness of treating mice bearing premalignant oral lesions with PD-1 antibodies.
Levingston CA; Young MR
Int J Cancer; 2017 Apr; 140(7):1609-1619. PubMed ID: 27914100
[TBL] [Abstract][Full Text] [Related]
8. A novel humanized anti-PD-1 monoclonal antibody potentiates therapy in oral squamous cell carcinoma.
Cai Y; Wang F; Liu Q; Li Z; Li D; Sun Z
Invest New Drugs; 2019 Oct; 37(5):799-809. PubMed ID: 30368626
[TBL] [Abstract][Full Text] [Related]
9. Expression of programmed cell death-ligand 1 in oral squamous cell carcinoma and oral leukoplakia is associated with disease progress and CD8+ tumor-infiltrating lymphocytes.
Chen XJ; Tan YQ; Zhang N; He MJ; Zhou G
Pathol Res Pract; 2019 Jun; 215(6):152418. PubMed ID: 31027907
[TBL] [Abstract][Full Text] [Related]
10. The effect of Curcumin on multi-level immune checkpoint blockade and T cell dysfunction in head and neck cancer.
Liu L; Lim MA; Jung SN; Oh C; Won HR; Jin YL; Piao Y; Kim HJ; Chang JW; Koo BS
Phytomedicine; 2021 Nov; 92():153758. PubMed ID: 34592487
[TBL] [Abstract][Full Text] [Related]
11. Expression of immunoregulatory molecules PD-L1 and PD-1 in oral cancer and precancerous lesions: A cohort study of Japanese patients.
Kouketsu A; Sato I; Oikawa M; Shimizu Y; Saito H; Takahashi T; Kumamoto H
J Craniomaxillofac Surg; 2019 Jan; 47(1):33-40. PubMed ID: 30466788
[TBL] [Abstract][Full Text] [Related]
12. Regulation of PD-L1 expression in a high-grade invasive human oral squamous cell carcinoma microenvironment.
Hirai M; Kitahara H; Kobayashi Y; Kato K; Bou-Gharios G; Nakamura H; Kawashiri S
Int J Oncol; 2017 Jan; 50(1):41-48. PubMed ID: 27922697
[TBL] [Abstract][Full Text] [Related]
13. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
14. PD-1/PD-L1, Treg-related proteins, and tumour-infiltrating lymphocytes are associated with the development of oral squamous cell carcinoma.
Kujan O; Agag M; Smaga M; Vaishnaw Y; Idrees M; Shearston K; Farah CS
Pathology; 2022 Jun; 54(4):409-416. PubMed ID: 34872754
[TBL] [Abstract][Full Text] [Related]
15. Contributions of T cell dysfunction to the resistance against anti-PD-1 therapy in oral carcinogenesis.
Wen L; Lu H; Li Q; Li Q; Wen S; Wang D; Wang X; Fang J; Cui J; Cheng B; Wang Z
J Exp Clin Cancer Res; 2019 Jul; 38(1):299. PubMed ID: 31291983
[TBL] [Abstract][Full Text] [Related]
16. Tumor-derived exosomes promote carcinogenesis of murine oral squamous cell carcinoma.
Razzo BM; Ludwig N; Hong CS; Sharma P; Fabian KP; Fecek RJ; Storkus WJ; Whiteside TL
Carcinogenesis; 2020 Jul; 41(5):625-633. PubMed ID: 31245809
[TBL] [Abstract][Full Text] [Related]
17. Combination of bexarotene and the retinoid CD1530 reduces murine oral-cavity carcinogenesis induced by the carcinogen 4-nitroquinoline 1-oxide.
Tang XH; Osei-Sarfo K; Urvalek AM; Zhang T; Scognamiglio T; Gudas LJ
Proc Natl Acad Sci U S A; 2014 Jun; 111(24):8907-12. PubMed ID: 24927566
[TBL] [Abstract][Full Text] [Related]
18. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs.
Allard B; Pommey S; Smyth MJ; Stagg J
Clin Cancer Res; 2013 Oct; 19(20):5626-35. PubMed ID: 23983257
[TBL] [Abstract][Full Text] [Related]
19. Targeting IL-17alpha to promote anti-PD-1 therapy effect by screening the tumor immune microenvironment in a mouse oral carcinogenesis model.
Wang S; Yu X; Li F; Fan H; Zhao E; Hu Z
Cancer Biomark; 2021; 31(4):339-350. PubMed ID: 33896829
[TBL] [Abstract][Full Text] [Related]
20. MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1/PD-L1-mediated lymphoma cell interaction with CD8+T cells.
Zheng Z; Sun R; Zhao HJ; Fu D; Zhong HJ; Weng XQ; Qu B; Zhao Y; Wang L; Zhao WL
Mol Cancer; 2019 Mar; 18(1):54. PubMed ID: 30925928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
